AzTrials
AzTrials

End-stage Lung DiseaseNCT07384507

Perioperative Recovery Outcomes With a Spontaneous Breathing Strategy in Older Lung Transplant Recipients

A study testing Lung transplantation that preserves spontaneous breathing function in people with End-stage Lung Disease, run by The First Affiliated Hospital of Guangzhou Medical University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this prospective, multicenter, single-arm cohort study is to learn whether a lung transplantation approach that preserves patients' spontaneous breathing during surgery can improve early recovery in adults aged 70 years and older undergoing allogeneic lung transplantation. Read more about this study

Who is it for?
Ages 70 years and older
Conditions the study is for
End-stage Lung Disease
What is being tested?
Lung transplantation that preserves spontaneous breathing function
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
No sites listed yet
Study dates
30 Jan 2026to 30 Jan 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 70 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

[1] Inclusion Criteria

  1. Age and informed consent: Age ≥70 years; able to understand the study and provide written informed consent, or, where permitted by ethics and applicable regulations, consent may be provided by a legally authorized representative (LAR)/authorized surrogate; willing and able to complete follow-up.
  2. Transplant candidacy: Listed in CLuTR or the lung transplant waiting list of the participating center, with a plan to undergo allogeneic lung transplantation.
  3. Preoperative support status: Not receiving ongoing invasive mechanical ventilation (endotracheal intubation or tracheostomy) preoperatively, and not receiving ECMO or other extracorporeal life support.
  4. Minimum key organ function: LVEF ≥40%; eGFR ≥40 mL/min/1.73 m²; no evidence of acute liver failure or decompensated cirrhosis/portal hypertension; ASA physical status ≤ IV (American Society of Anesthesiologists classification).
  5. Infection and communicable diseases: No evidence of active infection; no active tuberculosis; HIV/HBV/HCV status meets the center's transplant requirements (e.g., undetectable viral load, as applicable).
  6. Rehabilitation and support: Demonstrated potential for postoperative rehabilitation (able to participate in training) and reliable caregiving support (at least one primary caregiver).

[2] Exclusion Criteria

  1. Informed consent/adherence: Refusal or withdrawal of informed consent; investigator judgment that follow-up cannot be completed or there is recurrent severe non-adherence.
  2. Transplant type: Re-transplantation, multi-organ transplantation, or planned lobar lung transplantation.
  3. Recent major cardio-cerebrovascular events: Acute coronary syndrome/myocardial infarction or stroke within the past 30 days.
  4. Severe organ dysfunction/acute failure: LVEF <40%; eGFR <40 mL/min/1.73 m²; acute liver failure or decompensated cirrhosis/portal hypertension; acute renal failure requiring dialysis with low likelihood of recovery; significant preoperative neuropsychiatric disorders or altered consciousness.
  5. High risk of severe infection: Septic shock; active extrapulmonary/disseminated infection; active tuberculosis; detectable HIV viral load (or otherwise not meeting the center's transplant criteria).
  6. High bleeding risk: Severe bronchiectasis without preoperative vascular intervention or not correctable/mitigable.
  7. Malignancy: Active malignancy or tumors with high risk of recurrence or high cancer-related mortality risk.
  8. Extreme body habitus/major deformity: BMI ≥35 kg/m² or BMI <16 kg/m²; clearly diagnosed severe chest wall deformity or spinal deformity.
  9. Substance use/dependence: Current use of cigarettes, e-cigarettes, smoked/vaped cannabis, or intravenous drug use.
  10. Tubeless/spontaneous-breathing strategy not safely feasible: Deemed by the anesthesia team to have a difficult airway or unsafe supraglottic/non-intubated airway management (e.g., anticipated intraoperative airway difficulty, pharyngeal/laryngeal stenosis not suitable for a laryngeal mask), including but not limited to: Mallampati class >III, mouth opening <3 cm, thyromental distance <5 cm, or significant airway anatomical variations (e.g., aberrant right upper lobe bronchial takeoff with planned right lung transplantation) where safe management with LMA/single-lumen approaches is judged unlikely.
  11. Donor/donor lung limitations: Donor age >60 years; donor mechanical ventilation >14 days; positive donor airway microbiology considered unacceptable by the transplant team.
  12. Protected populations: Pregnant or breastfeeding women.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Jiaqin Zhang, M.D. contact

+8613662833144

zhang_jqwow@163.com

About this study

Official title: Evaluation of Perioperative Recovery With a Spontaneous Breathing-Preserving Strategy in Older Lung Transplant Recipients: A Prospective Multicenter Single-Arm Cohort Study

The goal of this prospective, multicenter, single-arm cohort study is to learn whether a lung transplantation approach that preserves patients' spontaneous breathing during surgery can improve early recovery in adults aged 70 years and older undergoing allogeneic lung transplantation.

The main questions it aims to answer are whether, in adult lung transplant recipients aged 70 years and older, an anesthesia-surgical strategy designed to preserve spontaneous breathing is associated with better early postoperative recovery, specifically in terms of the need for postoperative invasive mechanical ventilation, postoperative length of hospital stay, and perioperative survival.

Participants will undergo lung transplantation using a standardized anesthesia-surgical strategy intended to preserve spontaneous breathing, with predefined criteria for conversion to tracheal intubation and/or ECMO if clinically needed. They will receive standardized perioperative management and routine postoperative care (including ICU monitoring, rehabilitation, and recovery support) as determined by the transplant team. Participants will be assessed throughout hospitalization and followed for postoperative complications and outcomes through discharge and up to 30 days after surgery.

Read the detailed description

This prospective, multicenter, single-arm cohort study (BREATH-Elderly) is designed to evaluate the clinical effectiveness and safety of an anesthesia-surgical strategy intended to preserve spontaneous breathing in adult lung transplant recipients aged 70 years and older. The primary objective is to characterize early postoperative recovery under this standardized pathway, with a focus on (1) postoperative invasive mechanical ventilation (IMV) requirement, (2) postoperative length of hospital stay (LOS), and (3) perioperative survival (from the start of transplantation to hospital discharge or postoperative day 30, whichever occurs first).

Eligible participants are adults aged ≥70 years who are listed for allogeneic lung transplantation and meet prespecified perioperative safety thresholds (e.g., not receiving ongoing invasive mechanical ventilation or ECMO preoperatively; acceptable baseline cardiac and renal function; no evidence of active infection; and adequate rehabilitation potential and caregiver support). Key exclusions include retransplantation or multi-organ transplantation, recent major cardiovascular/cerebrovascular events, severe end-organ failure, active malignancy, extreme body habitus (e.g., BMI <16 or ≥35 kg/m²), ongoing substance use, and scenarios judged by the anesthesia team to make a preserved spontaneous-breathing pathway unsafe (e.g., predicted difficult airway or inability to safely manage the airway with a laryngeal mask-based approach).

All enrolled participants will undergo lung transplantation using a standardized preserved spontaneous-breathing anesthesia-surgical pathway, typically based on total intravenous anesthesia with airway management using a laryngeal mask airway and continuous monitoring of oxygenation and ventilation. The protocol includes predefined rescue escalation criteria and standardized procedures for conversion when clinically indicated. Triggers for conversion may include, but are not limited to: persistent hypoxemia (e.g., SpO₂ <85% despite assisted ventilation), severe hypercapnia with acidosis and accompanying hemodynamic/arrhythmic instability (e.g., PaCO₂ ≥80 mmHg with repeated pH <7.25 and circulatory/arrhythmic changes), unstable surgical field due to marked mediastinal movement refractory to adjustment, major intraoperative bleeding impairing operative safety, and abnormal airway secretions (e.g., increased or bloody sputum with a >30% reduction in tidal volume or elevated airway pressure when assisted ventilation is required). If conversion is required, the protocol specifies intubation approach options (e.g., single-lumen tube plus bronchial blocker or double-lumen tube when lung isolation is necessary) and immediate initiation of lung-protective ventilation. Postoperative care, including immunosuppression and infection prevention, follows routine standards at each participating transplant center and is recorded in the case report form. Participants are assessed throughout the index hospitalization, with key postoperative complications captured through discharge and up to 30 days after surgery, and additional follow-up items (e.g., 90-day survival/readmission/interventions) recorded where applicable.

The primary endpoint is a composite of three early recovery indicators (reported both as a composite and as individual components): (1) postoperative IMV requirement in the early postoperative period (including events such as re-intubation/tracheostomy and/or new or escalated extracorporeal respiratory support as defined in the protocol), (2) postoperative LOS, and (3) perioperative survival to discharge or postoperative day 30. Secondary endpoints include intraoperative and anesthesia-related measures (e.g., operative/anesthesia time, blood loss, perioperative medication exposure, success rate of removing the airway device in the operating room, time to first effective communication), ICU length of stay, in-hospital resource utilization/cost categories, and a prespecified list of postoperative complications (e.g., primary graft dysfunction graded at standard time points, respiratory support escalation events, infections, bleeding requiring re-intervention, AKI and renal replacement therapy, major cardiovascular/cerebrovascular events, rejection episodes, and thrombotic events). Outcomes will be summarized descriptively and compared against each center's historical outcomes under conventional intubated strategies using appropriate one-sample methods; multivariable models may be used to adjust for important clinical factors (e.g., diagnosis, intraoperative ECMO use, and procedural complexity) when warranted.

The study is expected to demonstrate that, in carefully selected recipients aged ≥70 years, a standardized preserved spontaneous-breathing strategy is feasible and can be implemented with structured rescue pathways, and may be associated with a higher proportion of patients avoiding postoperative IMV, a shorter postoperative hospital stay, and maintained perioperative survival within an acceptable safety profile. These findings are intended to support broader implementation guidance and inform the design of subsequent comparative studies in elderly lung transplant populations.

Being tested
Lung transplantation that preserves spontaneous breathing function
Keywords
Lung transplantation, Enhanced Recovery After Surgery

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lung transplantation that preserves spontaneous breathing functionProcedure or surgery

    This intervention uses a spontaneous-breathing-preserving anesthesia strategy during lung transplantation, which differs from conventional management based on endotracheal intubation and invasive mechanical ventilation. A supraglottic airway (laryngeal mask airway) is used when feasible instead of endotracheal intubation to maintain spontaneous breathing throughout the procedure. Neuromuscular blocking agents are minimized, and regional nerve blocks (such as intercostal nerve blocks or paravertebral blocks) are used to control pain and suppress cough while preserving the patient's ability to breathe independently. After surgery, patients receive protocol-guided noninvasive respiratory support (for example, high-flow nasal oxygen or noninvasive ventilation), with the goal of avoiding routine invasive mechanical ventilation.

Study groups in NCT07384507
Study groupRoleWhat they receive
Tubeless LTx GroupExperimentalAll participants receive lung transplantation under a standardized spontaneous-breathing-preserving ("tubeless") pathway. After anesthesia induction, a supraglottic airway (laryngeal mask airway) is used when feasible with regional nerve blocks and multimodal sedation/analgesia to control pain and cough while maintaining spontaneous breathing. Muscle relaxants are minimized; ventilatory assistance is provided only as needed with low airway pressures. Postoperatively, patients are managed in the intensive care unit with spontaneous breathing and protocol-guided noninvasive respiratory support. Conversion to endotracheal intubation, invasive mechanical ventilation, and/or extracorporeal membrane oxygenation is allowed if predefined safety criteria are met.
Receives: Procedure: Lung transplantation that preserves spontaneous breathing function

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Requiring Postoperative Invasive Mechanical Ventilation (IMV) During Index Hospitalization

    Number of participants who require postoperative invasive mechanical ventilation (IMV) delivered via an endotracheal tube or tracheostomy tube at any time after leaving the operating room and before hospital discharge (including in-hospital death).

    Measured: From ICU admission immediately after leaving the operating room until hospital discharge or in-hospital death, assessed up to 90 days postoperatively (if hospitalization extends beyond 90 days, events after day 90 will not be counted for this outcome).

  2. Postoperative Hospital Length of Stay (Days) During Index Hospitalization

    The number of days from the end of surgery (postoperative Day 0) to the date the participant is discharged from the index hospitalization, according to institutional discharge criteria. Participants who die in hospital will be assigned length of stay through the date of in-hospital death.

    Measured: From end of surgery (postoperative Day 0) until hospital discharge or in-hospital death (index hospitalization), assessed up to 90 days.

  3. Rate of Perioperative Survival

    Perioperative survival is defined as the proportion of participants who remain alive from the start of transplant surgery through hospital discharge or postoperative Day 30, whichever occurs first. Participants who die before discharge or before postoperative Day 30 will be counted as non-survivors for this outcome.

    Measured: From start of transplant surgery through hospital discharge or postoperative Day 30, whichever occurs first.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Feb 2026
  2. Study start30 Jan 2026 (estimated)
  3. Primary completion1 Dec 2028 (estimated)
  4. Study completion30 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07384507
Sponsor's protocol ID
BREATH-Elderly
Status last verified
Jan 2026
First submitted
21 Jan 2026
Last updated
3 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: We will share de-identified individual participant data (IPD) underlying the analyses of this clinical study, limited to baseline and perioperative variables. Baseline IPD will include demographics (e.g., age, sex), primary diagnosis, key comorbidities, and transplant-relevant preoperative measures and donor/recipient characteristics recorded in structured fields. Perioperative IPD will include operative and anesthesia strategy, airway management, intraoperative/early postoperative respiratory and hemodynamic parameters, major perioperative interventions (e.g., ECMO use), and key in-hospital outcomes during the index hospitalization (e.g., need for postoperative IMV, complications, ICU/hospital length of stay, and in-hospital mortality). The study protocol and statistical analysis plan will also be shared. All direct identifiers will be removed and dates will be shifted/aggregated as needed to protect privacy.

Questions about this trial

What is this clinical trial studying?

A study testing Lung transplantation that preserves spontaneous breathing function in people with End-stage Lung Disease, run by The First Affiliated Hospital of Guangzhou Medical University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jiaqin Zhang, M.D. (+8613662833144, zhang_jqwow@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Requiring Postoperative Invasive Mechanical Ventilation (IMV) During Index Hospitalization (time frame: From ICU admission immediately after leaving the operating room until hospital discharge or in-hospital death, assessed up to 90 days postoperatively (if hospitalization extends beyond 90 days, events after day 90 will not be counted for this outcome).). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in